scholarly journals p38 MAPK, but not ERK1/2, is critically involved in the cytotoxicity of the novel vascular disrupting agent combretastatin A4

2007 ◽  
Vol 122 (8) ◽  
pp. 1730-1737 ◽  
Author(s):  
Haitian Quan ◽  
Yongping Xu ◽  
Liguang Lou
Keyword(s):  
P38 Mapk ◽  
The Novel ◽  
Vascular Disrupting Agent ◽  
Combretastatin A4 ◽  
Vascular Disrupting

Combretastatin A4 phosphate: a novel vascular disrupting agent

2010 ◽  
Vol 6 (8) ◽  
pp. 1219-1228 ◽  
Author(s):  
Govardhanan Nagaiah ◽  
Scot C Remick
Keyword(s):  
Vascular Disrupting Agent ◽  
Combretastatin A4 ◽  
Vascular Disrupting

Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel

2011 ◽  
Vol 30 (3) ◽  
pp. 1065-1073 ◽  
Author(s):  
Michael Millward ◽  
Paul Mainwaring ◽  
Alain Mita ◽  
Kristine Federico ◽  
G. K. Lloyd ◽  
...  
Keyword(s):  
Phase 1 ◽  
The Novel ◽  
Phase 1 Study ◽  
Vascular Disrupting Agent ◽  
Vascular Disrupting

Abstract LB-202: Phase 1 dose escalation trial of the novel vascular disrupting agent NPI-2358

2008 ◽  
Author(s):  
Monica Mita ◽  
Matthew A Spear ◽  
Lorrin K Yee ◽  
K P Papadopoulos ◽  
Elisabeth Heath ◽  
...  
Keyword(s):  
Dose Escalation ◽  
Phase 1 ◽  
The Novel ◽  
Vascular Disrupting Agent ◽  
Vascular Disrupting

scholarly journals TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice

2011 ◽  
Vol 121 (5) ◽  
pp. 1969-1973 ◽  
Author(s):  
Abigail F. Welford ◽  
Daniela Biziato ◽  
Seth B. Coffelt ◽  
Silvia Nucera ◽  
Matthew Fisher ◽  
...  
Keyword(s):  
Therapeutic Efficacy ◽  
Vascular Disrupting Agent ◽  
Combretastatin A4 ◽  
Vascular Disrupting

The vascular-disrupting agent, combretastatin-A4-phosphate, enhances neurogenic vasoconstriction in rat small arteries

2012 ◽  
Vol 695 (1-3) ◽  
pp. 104-111 ◽  
Author(s):  
Junjing Su ◽  
Britt E. Laursen ◽  
Yvonne Eskildsen-Helmond ◽  
Michael R. Horsman ◽  
Ulf Simonsen
Keyword(s):  
Vascular Disrupting Agent ◽  
Small Arteries ◽  
Combretastatin A4 ◽  
Neurogenic Vasoconstriction ◽  
Vascular Disrupting

The Novel Vascular Disrupting Agent ANG501 Induces Cell Cycle Arrest and Enhances Endothelial Cell Sensitivity to Radiation

2009 ◽  
Vol 2 ◽  
pp. CGM.S2596 ◽  
Author(s):  
Shona T. Dougherty ◽  
Sean E. Walker ◽  
Peter D. Davis ◽  
Graeme J. Dougherty
Keyword(s):  
Cell Cycle ◽  
Endothelial Cells ◽  
Normal Cell ◽  
Cell Cycle Progression ◽  
Stress Proteins ◽  
Vascular Disrupting Agent ◽  
Heat Shock Stress ◽  
Cell Cycling ◽  
Vascular Disrupting

The efficacy of approaches in which vascular disrupting agents (VDA) are used in combination with conventional chemotherapy and/or radiation therapy in the treatment of cancer might be improved if there were a better understanding of the cellular and molecular changes induced in normal and malignant cells as a result of VD A exposure. Toward this goal, murine endothelial cells were treated in vitro with ANG501, a novel stilbene VDA developed in our laboratory, and alterations in gene expression determined by genome-wide microarray analysis and subsequently confirmed by Western blot analysis. Among the genes that were shown to be induced upon brief exposure to non-cytotoxic doses of ANG501 were several involved in the control of cell cycle progression and apoptosis, including p21Wafl and the heat shock/stress proteins hsp25, hsp70 and anti-B-crystallin. Reflecting such induction, functional studies confirmed that normal cell cycling is temporarily inhibited following treatment with ANG501 such that the majority of cells accumulate at the radiation-sensitive G2/M phase of the cell cycle at 6 hr. The effects were transient and by 24 hr normal cell cycling had largely resumed. Combination experiments confirmed that endothelial cells treated 6 hr previously with ANG501 were more readily killed by radiation. Importantly, significant effects were evident at clinically relevant radiation doses. Taken together these findings emphasize the need to consider the radiosensitizing activity of VD As when developing therapies in which these promising compounds are used in combination with radiation.

scholarly journals Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent

2010 ◽  
Vol 103 (5) ◽  
pp. 597-606 ◽  
Author(s):  
J D Lickliter ◽  
A B Francesconi ◽  
G Smith ◽  
M Burge ◽  
A Coulthard ◽  
...  
Keyword(s):  
Phase I ◽  
Phase I Trial ◽  
Vascular Disrupting Agent ◽  
Vascular Disrupting
Sign in / Sign up

Export Citation Format

Share Document